Geovax Labs Inc Stock Price, News & Analysis

GeoVax Labs, Inc. (Nasdaq: GOVX) has initiated vaccine dosing in the Phase 2 trial of its COH04S1, a multi-antigenic SARS-CoV-2 vaccine targeting both spike and nucleocapsid proteins. This trial aims to evaluate COH04S1 as a universal booster for current FDA-approved vaccines. The Phase 1 portion focused on safety and immunogenicity in healthy individuals, while Phase 2 involves 60 previously vaccinated participants. Positive expectations arise from COH04S1's potential to offer enhanced immune responses against variants like Omicron. Results are anticipated in early 2022.

GeoVax Labs has received a Notice of Allowance for its patent application aimed at developing a vaccine for malaria, utilizing modified vaccinia Ankara (MVA) vectors. This innovative platform targets multiple stages of the malaria parasite, addressing a significant public health crisis with 228 million infections and 405,000 deaths annually. GeoVax's focus remains on its COVID-19 vaccine in Phase 2 trials, alongside cancer therapies. The company emphasizes its dedication to advancing vaccine innovations to enhance public health globally.

GeoVax Labs (NASDAQ: GOVX) presented promising preclinical results for its investigational vaccines against Sudan and Marburg viruses at the World Vaccine & Immunotherapy Congress. Using the GV-MVA-VLP platform, the vaccines provided 100% protection in lethal guinea pig models and safeguarded nonhuman primates from severe symptoms and death. This efficacy, alongside the evident immune responses, underscores the potential for further clinical development. The research received federal funding, signaling a commitment to advancing vaccine safety and effectiveness against hemorrhagic fevers.

GeoVax Labs (Nasdaq: GOVX) is advancing its investigational universal vaccine, GEO-CM02, to combat evolving SARS-CoV-2 variants, including Omicron. At the World Vaccine & Immunotherapy Congress, Chief Scientific Officer Mark J. Newman highlighted the vaccine's broad immune response potential, leveraging their GV-MVA-VLP™ platform. The vaccine aims to induce protection against multiple coronavirus proteins, promising enhanced durability and efficacy. Ongoing studies reported positive results in small animal trials, showing immune responses after a single dose, crucial in tackling emerging variants.

GeoVax Labs, Inc. (Nasdaq: GOVX) recently presented data on its COVID-19 vaccine candidate, GEO-CM02, at the Vaccine World Asia Congress. Developed using the GV-MVA-VLP™ platform, this vaccine aims to provide broader immunity against evolving SARS-CoV-2 variants by targeting multiple structural proteins. Efficacy studies show promise, including protection against the Beta variant. Additionally, GeoVax's collaboration with City of Hope on the multi-antigenic vaccine COH04S1 is progressing through Phase 2 trials, reinforcing its commitment to combat COVID-19 in vulnerable populations.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced the issuance of a Notice of Allowance for Patent Application No. 16/068,527 for a novel immunotherapy development targeting tumor-associated antigens. This patent expands GeoVax's intellectual property portfolio to over 70 granted or pending applications. The company is progressing with its MVA-VLP-MUC1 immunotherapy candidates, which show promise against several cancers, and has acquired rights to Gedeptin®, a patented product for solid tumors in clinical trials. The advancements signal significant prospects for future therapeutic applications.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced its participation in significant scientific conferences. On November 17, Chief Scientific Officer Mark Newman, PhD, will present on a universal coronavirus vaccine at the Vaccine World Asia Congress. At the World Vaccine & Immunotherapy Congress in San Diego from November 30 to December 2, he will discuss VLP-based COVID-19 vaccine development, while Senior Scientist Mary Hauser, PhD, will present on vaccines against hemorrhagic fevers.

GeoVax specializes in developing vaccines for infectious diseases and cancer using advanced platforms.

GeoVax Labs, Inc. (GOVX) reported a net loss of $1.95 million ($0.31 per share) for Q3 2021, a significant increase from $570,648 ($0.73 per share) in Q3 2020. The company has entered an exclusive licensing agreement with City of Hope for COH04S1, a COVID-19 vaccine candidate, currently undergoing a Phase 2 trial for immunocompromised patients. GeoVax also acquired Gedeptin®, a novel gene therapy for solid tumors, with a Phase 1/2 trial enrolling patients. Cash balances rose to $18.1 million, aided by stock sales and warrant exercises.

GeoVax Labs (Nasdaq: GOVX) announced an exclusive licensing agreement with City of Hope to develop a multi-antigenic SARS-CoV-2 vaccine, COH04S1, aimed at immunocompromised patients. Currently in a Phase 2 trial, the vaccine could serve as a booster against COVID-19 worldwide. COH04S1 uniquely includes both spike and nucleocapsid proteins, prompting a rapid immune response. The agreement enhances GeoVax's pipeline alongside its MVA-based vaccine technology, targeting multiple infectious diseases. Financial terms remain undisclosed, with a conference call for financial results scheduled on Nov. 11, 2021.